Hormonal
Marine-derived n-3 polyunsaturated fatty acid (PUFA) supplementation significantly lowers fasting blood levels of C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in subjects with chronic non-autoimmune disease, chronic autoimmune disease, and healthy subjects.
If you are dealing with chronic inflammation, adding marine-derived omega-3 supplements (fish oil) can significantly lower inflammatory markers like CRP and IL-6. This benefit is most pronounced in non-obese individuals (BMI < 30) and those with chronic diseases. For general health, it helps, but for significant inflammation reduction, consistency and duration matter.
Marine-derived n-3 PUFAs supplementation had a significant lowering effect on TNF-a, IL-6 and CRP in three groups of subjects (subjects with chronic non-autoimmune disease, subjects with chronic autoimmune disease and healthy subjects).
Why this rating
Meta-analysis of 68 RCTs with 4601 subjects provides high-quality aggregate evidence, though heterogeneity was noted.
Source
Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis
Kelei Li et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0088103
More from this paper
- The anti-inflammatory effect of marine-derived n-3 PUFAs on CRP is significantly weakened or absent in subjects with a BMI greater than 30 kg/m2.Good
- Longer duration of marine-derived n-3 PUFAs supplementation leads to a greater lowering effect on IL-6 and TNF-α in subjects with chronic non-autoimmune disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →